HEB - Hemispherx Biopharma, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.3052
-0.0033 (-1.07%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.3085
Open0.3050
Bid0.0000 x 1800
Ask0.0000 x 800
Day's Range0.3030 - 0.3124
52 Week Range0.2800 - 0.6500
Volume74,557
Avg. Volume607,093
Market Cap14.271M
Beta0.17
PE Ratio (TTM)N/A
EPS (TTM)-0.2600
Earnings DateMay 18, 2017 - May 19, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.52
Trade prices are not sourced from all markets
  • GlobeNewswire10 days ago

    Hemispherx Files Positive Safety Report on Intranasal Use of Ampligen in Combination with FluMist Influenza Vaccine

    Hemispherx Biopharma, Inc. (NYSE American:HEB) announced the filing of a clinical study report on AMP-600, a Phase I/II trial of intranasal Ampligen® in combination with FluMist® influenza vaccine with the U.S. Food and Drug Administration. Hemispherx is a research and development and, consistent with its commercial and early access program approvals, an emerging commercial development company focused on unmet medical needs in immunology, with a special emphasis in immuno-oncology. The two-stage randomized, double-blinded, placebo-controlled, clinical trial assessed the immunogenicity and safety of intranasal FluMist administered sequentially with intranasal Ampligen.

  • GlobeNewswire16 days ago

    Hemispherx Notes the Importance of Immunizations During Upcoming National Immunization Awareness Month and Potential of Ampligen in Influenza Vaccine Strategies

    Hemispherx Biopharma, Inc. (NYSE American:HEB), an immuno-pharma R&D company focused on unmet medical needs in immunology, is pleased to enthusiastically support National Immunization Awareness Month (NIAM), which is observed annually during August. NIAM is designed “to celebrate the benefits of vaccination and highlight the importance of vaccination for people of all ages,” according to its sponsor, the National Public Health Information Coalition. To learn more about NIAM, please click here.

  • ACCESSWIRE20 days ago

    Anthera Pharma and Three Additional Stocks Under Scanner in the Biotech Space

    LONDON, UK / ACCESSWIRE / June 29, 2018 / If you want a free Stock Review on ANTH sign up now at www.wallstequities.com/registration. The nature of the operations of firms in the Biotech industry makes equities in this space more suited to aggressive, risk-tolerant investors.

  • GlobeNewswire22 days ago

    Hemispherx Opens FDA-Approved Reimbursement Based Expanded Access Treatment Program for ME/CFS to New Enrollees at Approved Clinical Sites in Nevada and North Carolina

    Hemispherx Biopharma, Inc. (NYSE American:HEB) has announced the immediate expansion of its Treatment Protocol/Expanded Access Programs for ME/CFS in the United States, known as AMP-511, to new enrollees for the first time in more than a year. This opportunity to expand the scope of AMP-511 is based on the successful completion of the first phase of its Ampligen manufacturing initiative producing sufficient quantities of Ampligen to support new enrollees in this FDA-approved program. Additional enrollees will be added as supplies of Ampligen expand with the successful fill and finish of additional commercial-sized lots similar to the 8,500 vials just released for human use.

  • GlobeNewswire27 days ago

    Report: Developing Opportunities within Sonic Automotive, PJT Partners, YRC Worldwide, SecureWorks, Manhattan Associates, and Hemispherx BioPharma — Future Expectations, Projections Moving into 2018

    NEW YORK, June 22, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Sonic ...

  • GlobeNewswirelast month

    Hemispherx Releases First 8,500 Vial Lot of Ampligen to Supply Expanded Access Programs in the United States, Europe and Canada for ME/CFS and Pancreatic Cancer and Announces Successful Finish of Second Commercial Size Lot

    Hemispherx Biopharma, Inc. (NYSE American:HEB) has announced the successful completion of the first phase of its Ampligen production plan. The first commercial-sized lot of Ampligen, which completed cGMP manufacturing on April 4, 2018, has passed all required testing for regulatory release for human use. This is the second such successful commercial sized production run in the last two months.

  • GlobeNewswirelast month

    Hemispherx Announces New Data Showing Ampligen’s Positive Role in Reprograming Tumor Microenvironment

    Hemispherx Biopharma, Inc. (NYSE American:HEB) announced today that its TLR3 agonist Ampligen outperformed two other TLR3 agonists, poly IC and natural double stranded RNA, in creating an enhanced tumor microenvironment for checkpoint blockage therapy. Hemispherx is an advanced specialty pharmaceutical company engaged in the treatment of serious and debilitating disorders. In a head-to-head study in explant culture models, Ampligen activated the TLR3 pathway and promoted an accumulation of killer T cells but, unlike the other two TLR3 agonists, it did so without causing regulatory T cell (Treg) attraction.

  • GlobeNewswire2 months ago

    Hemispherx Biopharma and Roswell Park Plan Phase I/II Study of Ampligen Plus Checkpoint Inhibitors

    Roswell Park Comprehensive Cancer Center (Roswell Park) and Hemispherx Biopharma, Inc. (NYSE American:HEB) plan to expand their existing scientific collaboration to advance the clinical development of Ampligen – an investigational immune-enhancing TLR3 agonist – which has shown promise in preclinical studies when combined with checkpoint inhibitors (CPIs). The parties have executed a Memorandum of Understanding (“MOU”) designed to further assess the clinical potential of Ampligen in treating certain cancers. A contemplated phase I/II study will evaluate the potential of Ampligen to enhance the immune mediated effects of CPIs in patients with advanced solid tumors.

  • How Has Hemispherx Biopharma Inc’s (NYSEMKT:HEB) Performed Against The Industry?
    Simply Wall St.2 months ago

    How Has Hemispherx Biopharma Inc’s (NYSEMKT:HEB) Performed Against The Industry?

    After reading Hemispherx Biopharma Inc’s (AMEX:HEB) most recent earnings announcement (31 March 2018), I found it useful to look back at how the company has performed in the past andRead More...

  • ACCESSWIRE2 months ago

    Complimentary Technical Snapshots on Heat Biologics and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / May 24, 2018 / If you want a free Stock Review on HTBX sign up now at www.wallstequities.com/registration. Today, WallStEquities.com has selected the following stocks for review: Heat Biologics Inc. (NASDAQ: HTBX), Hemispherx Biopharma Inc. (NYSE AMER: HEB), iBio Inc. (NYSE: IBIO), and Idera Pharmaceuticals Inc. (NASDAQ: IDRA).

  • GlobeNewswire2 months ago

    CORRECTING AND REPLACING: Hemispherx Biopharma Reports First Quarter 2018 Financial Results and Provides Business Update

    In a release issued earlier today by Hemispherx Biopharma, Inc. (NYSE American:HEB) with the same headline, the net loss from operations was incorrect in the fourth paragraph. Hemispherx Biopharma, Inc. (NYSE American:HEB), an advanced specialty pharmaceutical company engaged in the treatment of serious and debilitating disorders through the development of its immunology products Ampligen® and Alferon®, today announced its financial results for the first quarter ended March 31, 2018. “We made significant progress in the quarter that just ended, including significant improvements to our balance sheet, the production of the equivalent of more than 8,500 vials of Ampligen at our contract fill and finish manufacturer, the expansion of our Ampligen supply agreements for early access programs in Canada and Europe under the management of myTomorrows, and the continuation of our plans to start advanced clinical trials of Ampligen as a single agent and a combination immuno-oncology therapy,” said Thomas K. Equels, Hemispherx’s chief executive officer.

  • GlobeNewswire2 months ago

    Hemispherx Biopharma Reports First Quarter 2018 Financial Results and Provides Business Update

    Hemispherx Biopharma, Inc. (NYSE American:HEB), an advanced specialty pharmaceutical company engaged in the treatment of serious and debilitating disorders through the development of its immunology products Ampligen® and Alferon®, today announced its financial results for the first quarter ended March 31, 2018. “We made significant progress in the quarter that just ended, including significant improvements to our balance sheet, the production of the equivalent of more than 8,500 vials of Ampligen at our contract fill and finish manufacturer, the expansion of our Ampligen supply agreements for early access programs in Canada and Europe under the management of myTomorrows, and the continuation of our plans to start advanced clinical trials of Ampligen as a single agent and a combination immuno-oncology therapy,” said Thomas K. Equels, Hemispherx’s chief executive officer.

  • GlobeNewswire2 months ago

    Hemispherx to Present at the 4th Annual Immuno-Oncology: BD&L and Investment Forum

    Hemispherx Biopharma, Inc. (NYSE American:HEB) announced today that it will be presenting at the 4th Annual Immuno-Oncology: BD&L and Investment Forum on Friday, June 1 at 3:40PM CDT (the time may be subject to changes depending on the conference organizers) at the Waldorf Astoria Chicago Hotel in Chicago, Illinois. Hemispherx is a research and development company focused on unmet medical needs in immunology, with a special emphasis in immuno-oncology. It is also an emerging commercial development company, based upon commercial approvals of Alferon® in the United States and Argentina for refractory or recurring external genital warts and Argentina for patients who become refractory to or intolerant to recombinant alpha interferon, as well as regulatory approval of Ampligen® in Argentina for severe Chronic Fatigue Syndrome (CFS).

  • GlobeNewswire2 months ago

    Hemispherx to Present at the 8th Annual LD Micro Invitational

    Hemispherx Biopharma, Inc. (NYSE American:HEB) announced today that it will be presenting at the 8th Annual LD Micro Invitational on Monday, June 4 at 11:00 AM PT (the time may be subject to changes depending on the conference organizers) at the Luxe Sunset Boulevard Hotel in Bel Air, California. Hemispherx is a research and development company focused on unmet medical needs in immunology, with a special emphasis in immuno-oncology. It is also an emerging commercial development company, based upon commercial approvals of Alferon in the United States and Argentina for refractory or recurring external genital warts and Argentina for patients refractory to or intolerant to recombinant alpha interferon, as well as regulatory approval of Ampligen in Argentina for severe Chronic Fatigue Syndrome (CFS).

  • GlobeNewswire3 months ago

    Research Report Identifies Systemax, C&J Energy Services, Seritage Growth Properties, Hemispherx BioPharma, YRC Worldwide, and Westlake Chemical Partners LP with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, May 03, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Systemax ...

  • GlobeNewswire3 months ago

    Hemispherx Provides an Update to Stockholders Highlighting Cancer Focus and $10 Million Booked Since Start of Year Will Support Increased Production of Ampligen for Immuno-Oncology Clinical Trials

    Hemispherx Biopharma, Inc. (NYSE American:HEB) would like to share a letter with its stockholders today, highlighting 2017 results, recent achievements, and outlining plans to take the company forward with emphasis on the fast-growing field of immunotherapy in cancer settings, utilizing Ampligen – a potent TLR-3 agonist amplifying the immune response – to potentially increase the effectiveness of checkpoint drugs. As you probably know, we recently announced the completion of fill and finish operations for our first commercial-size lot of Ampligen at our Contract Manufacturing Organization (“CMO”). Roughly one-fourth of the recently completed Ampligen production (2,100 vials) will be shipped for its Early Access Programs.

  • GlobeNewswire3 months ago

    Hemispherx Announces Pricing of $2.57 Million Registered Direct Offering at a Premium to Market

    ORLANDO, Fla., April 20, 2018-- Hemispherx Biopharma, Inc., a research and development and emerging commercial growth company focused on unmet medical needs in immunology, with a special emphasis in immune-oncology, ...

  • ACCESSWIRE3 months ago

    Wired News – ArQule Inked Exclusive License Deal with Basilea for Derazantinib in the US, EU, Japan and Rest of World

    Stock Monitor: Hemispherx Biopharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free research report on ArQule, Inc. (NASDAQ: ARQL ). If ...